

Supplementary Table 3 Univariate and multivariate predictors of a sustained viral response (SVR) to HCV treatment with pegylated interferon alpha and ribavirin (n=550)

Predictor	Categories	SVR			Univariate analysis				Multivariate analysis			
		No	Yes	% Yes	OR	95% CI	<i>P</i>	<i>P</i> overall	OR	95% CI	<i>P</i>	<i>P</i> overall
Total		223	327	59.5								
Sex	Male	152	192	55.8	1				1			
	Female	71	135	65.5	1.50	1.05-2.15	0.025		1.43	0.98-2.08	0.065	
Age group at treatment start (years)	<35	30	60	66.7	1				1			
	35-44	60	98	62.0	0.82	0.47-1.41	0.465	0.016*	0.93	0.53-1.64	0.527	0.198*
	45-54	99	139	58.4	0.70	0.42-1.16	0.173		0.89	0.52-1.52	0.517	
	55+	34	30	46.9	0.44	0.23-0.85	0.015		0.59	0.30-1.19	0.297	
Weight (kg)	≤75	101	181	64.2	1				1			
	>75	118	145	55.1	0.71	0.50-1.00	0.048		0.91	0.56-1.48	0.710	
	Unknown [†]	4	1	20.0								
Body mass index (kg/m ²)	≤25	86	164	65.6	1				1			
	25 to <30	75	98	56.7	0.69	0.46-1.02	0.063	0.008*	0.71	0.47-1.08	0.110	0.028*
	≥30	46	48	51.1	0.55	0.34-0.89	0.014		0.58	0.35-0.96	0.033	
	Unknown	16	17	51.5								

Predictor	Categories	SVR			Univariate analysis				Multivariate analysis			
		No	Yes	% Yes	OR	95% CI	<i>P</i>	<i>P</i> overall	OR	95% CI	<i>P</i>	<i>P</i> overall
Aboriginal or Torres Strait Islander	No	211	315	59.9	1							
	Yes	10	8	44.4	0.53	0.21-1.38	0.194					
	Unknown [†]	2	4	66.7								
Country of birth	Australia	161	258	61.6	1				1			
	Other Caucasian [†]	43	38	46.9	0.56	0.35-0.91	0.015	0.087[§]	0.57	0.34-0.94	0.027	0.146 [§]
	East Asian	8	14	63.6	1.12	0.46-2.71	0.764		1.02	0.38-2.72	0.974	
	Other	8	17	68.0	1.35	0.57-3.20	0.723		1.25	0.49-3.16	0.644	
	Unknown [†]	3	0	0								
Injecting drug use	Never	57	89	61.0	1							
	Past	155	219	58.6	0.90	0.61-1.33	0.594	0.687 [§]				
	Current	10	19	65.5	1.22	0.53-2.80	0.528					
	Unknown [†]	1	0	0								
Treatment for drug dependency	Non IDU	54	84	60.9	1				1			
	IDU Never	96	131	57.7	0.88	0.57-1.35	0.552	0.078[§]	0.90	0.57-1.42	0.640	0.096 [§]
	IDU Past	20	52	72.2	1.67	0.90-3.10	0.104		1.53	0.80-3.00	0.201	
	IDU Current	43	48	52.8	0.72	0.42-1.23	0.224		0.64	0.36-1.14	0.127	
	Unknown	10	12	54.6								

Predictor	Categories	SVR			Univariate analysis				Multivariate analysis			
		No	Yes	% Yes	OR	95% CI	<i>P</i>	<i>P</i> overall	OR	95% CI	<i>P</i>	<i>P</i> overall
Alcohol consumption (g/day)	Never/past	127	172	57.5	1							
	Current ≤20	75	123	62.1	1.20	0.83-1.72	0.324	0.613 [§]				
	Current >20	14	21	60.0	1.10	0.54-2.24	0.769					
	Unknown	7	11	61.1								
Tobacco smoking status	Never daily	41	60	59.4	1							
	Previous daily	57	94	62.3	1.13	0.67-1.89	0.650	0.694 [§]				
	Current daily	122	169	58.1	0.95	0.60-1.50	0.812					
	Unknown [†]	3	4	57.1								
Cannabis smoking status	Never regular user	84	135	61.6	1							
	Past regular user	66	101	60.5	0.95	0.63-1.44	0.816	0.703 [§]				
	Current <weekly	24	32	57.1	0.83	0.46-1.50	0.539					
	Current >weekly but not daily	15	25	62.5	1.04	0.52-2.08	0.918					
	Current ≥daily	24	25	51.0	0.65	0.35-1.21	0.172					
	Unknown	10	9	47.4								
History of treated psychiatric illness	No	144	213	59.7	1							
	Depression	45	78	63.4	1.17	0.77-1.79	0.463	0.244 [§]				
	Other	32	33	50.8	0.70	0.41-1.18	0.182					
	Unknown [†]	2	3	60.0								

Predictor	Categories	SVR			Univariate analysis				Multivariate analysis			
		No	Yes	% Yes	OR	95% CI	<i>P</i>	<i>P</i> overall	OR	95% CI	<i>P</i>	<i>P</i> overall
Diabetes	No	201	306	60.4	1							
	Yes	14	11	44.0	0.52	0.23-1.16	0.109					
	Unknown	8	10	55.6								
HIV positive	No	103	169	62.1	1				1			
	Yes	11	6	35.3	0.33	0.12-0.93	0.035		0.28	0.10-0.82	0.020	
	Unknown	109	152	58.2								
HBsAg positive	No	172	250	59.2	1							
	Yes	5	8	61.5	1.10	0.35-3.42	0.868					
	Unknown	46	59	60.0								
HBcAb positive	No	91	138	60.3	1							
	Yes	65	71	52.2	0.72	0.47-1.11	0.133					
	Unknown	76	118	63.4								
Duration of infection (years)	<10 years	42	84	66.7	1				1			
	10-19yrs	57	91	61.5	0.80	0.49-1.31	0.374	0.016*	0.83	0.49-1.40	0.480	0.101*
	20+	116	137	54.2	0.59	0.38-0.92	0.020		0.66	0.41-1.07	0.095	
	Missing	8	15	65.2								
Type of pegylated interferon alpha	2a	173	231	57.2	1				1			
	2b	50	96	65.8	1.44	0.97-2.13	0.071		1.50	0.99-2.28	0.057	

Predictor	Categories	SVR			Univariate analysis				Multivariate analysis			
		No	Yes	% Yes	OR	95% CI	<i>P</i>	<i>P</i> overall	OR	95% CI	<i>P</i>	<i>P</i> overall
Cirrhosis	No	186	301	61.8	1				1			
	Yes	22	13	37.1	0.37	0.18-0.74	0.005		0.38	0.18-0.81	0.011	
	Unknown	15	13	46.4								
HCV RNA level (IU/ml)	<400,000	47	92	66.2	1				1			
	≥400,000	136	184	57.5	0.69	0.46-1.05	0.081		0.75	0.49-1.17	0.205	
	Unknown	40	51	56.0								
HCV genotype	1	138	135	49.5	1				1			
	2 or 3	80	183	69.6	2.36	1.65-3.35	<0.001	<0.001[†]	2.45	1.70-3.52	<0.001	<0.001[§]
	Other	4	9	69.2	2.32	0.70-7.70	0.170		2.25	0.66-7.65	0.196	
	Unknown [†]	1	0	0								
ALT (U/L) ^{,†}	≤2 x ULN	52	84	61.8	1							
	2-3 x ULN	45	54	54.6	0.74	0.44-1.26	0.268	0.310 [†]				
	>3 x ULN	99	161	61.9	1.01	0.66-1.54	0.975					
	Unknown	27	28	50.9								
APRI score ^{,***}	≤1.5	136	218	61.6	1							
	>1.5	40	47	54.0	0.73	0.46-1.18	0.198					
	Unknown	47	62	56.9								
Cholesterol (mmol/L) ^{,††}	≤5	73	98	56.7	1				1			
	>5	9	41	82.0	3.39	1.55-7.42	0.002		4.07	1.78-9.29	0.001	
	Unknown	141	188	57.1								

		SVR			Univariate analysis			Multivariate analysis				
Predictor	Categories	No	Yes	% Yes	OR	95% CI	<i>P</i>	<i>P</i> overall	OR	95% CI	<i>P</i>	<i>P</i> overall
Triglycerides (mmol/L) ^{ll,††}	<1.7	60	94	61.0	1							
	≥1.7	16	30	65.2	1.20	0.60-2.38	0.609					
	Unknown	147	203	58.0								

Notes Table 3

ALT, alanine aminotransferase; HBsAg, Hepatitis B surface antigen; HBcAb, Hepatitis B core antibody, ULN = upper limit of normal

* *P*-value for linear trend

† Results for these categories were included in most frequent category for analysis

‡ Europe, New Zealand, Americas

§ *P*-value for heterogeneity

|| Result closest to, but within the year prior, to commencing treatment

¶ ULN for females=19 IU/L, ULN for males=30 IU/L (Prati et al. 2002)

** APRI score = ((AST/ULN)/platelet count)x100, where AST (aspartate aminotransferase) is in U/L, platelet count x10⁹, and ULN = 40 U/L (Wai et al. 2003)

†† Post hoc analysis